CompletedPhase 3

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

United States, Canada, Germany2,230 participantsStarted 2016-01-21

Plain-language summary

The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Fasting LDL-C ≥ 70 mg/dL * High cardiovascular risk (diagnosis of HeFH or ASCVD) * Be on maximally tolerated lipid-modifying therapy Exclusion Criteria: * Total fasting triglyceride ≥500 mg/dL * Renal dysfunction or nephrotic syndrome or history of nephritis * Body Mass Index (BMI) ≥50kg/m2 * Significant cardiovascular disease or cardiovascular event in the past 3 months

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

Timeframe: Up to approximately 52 weeks

Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder

Trial details

NCT IDNCT02666664

SponsorEsperion Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-02-21

Results submitted2020-03-20

View on ClinicalTrials.gov More Hypercholesterolemia trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

Timeframe: Up to approximately 52 weeks

Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis

Timeframe: Up to approximately 52 weeks

Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder